The clinical application of T cell immunotherapy depends on ex vivo modification and expansion of T cells for adoptive transfer. In preclinical models, the use of a purified, naive T cell subset enhances persistence and antitumor immunity; however, the majority of clinical studies rely on modification of mixed populations of T cells that contain only a small subset of highly functional T cells with less-differentiated phenotype. In this month's issue of the JCI, Klebanoff and colleagues uncover a Fas-mediated interaction between naive T cells and antigen-experienced T cells that drives differentiation and impairs adoptive immunotherapy. Further, they show that blockade of Fas signaling enhances antitumor immunity and increases survival in a mouse model of melanoma. Their work supports a growing body of evidence that the use of naive T cells enhances the efficacy of adoptive T cell therapy and suggests a new therapeutic strategy for preserving less-differentiated T cell populations.
Generating T cells for immunotherapy
Adoptive transfer of T lymphocytes engineered to achieve tumor specificity through the genetic insertion of either T cell receptors or chimeric antigen receptors (CARs) allows remarkable control of disseminated tumors across multiple phase I/II clinical studies in the academic setting (1, 2) . Some of these approaches are now further developed in multicenter studies supported by pharmaceutical companies. Manufacturing of engineered T cells is a key element for the realistic execution of multicenter clinical studies and for the future use of these cells in the clinical practice. Manufacturing of T cells is generally centralized to ensure reproducibility and aims at implementing standard operating procedures with minimized complexity. To this end, peripheral blood mononuclear cells (PBMCs) are frequently preferred for generating engineered T cell products. PBMCs are indeed readily obtained by gradient centrifugation and contain all circulating T cell subsets, from naive T cells to memory T cells, susceptible to effective transduction by viral vectors encoding the transgene following activation with CD3/ CD28 crosslinking antibodies and cytokines. Starting from PBMCs, T cell products can be obtained within two weeks of ex vivo culture, a time schedule compatible with an effective clinical application in many patients with refractory and resistant malignancies.
To select or not to selectthat is the question The composition of T cell subsets found in PBMCs of cancer patients is largely affected by several factors, including age, disease, and type of chemotherapy treatments received before blood procurement. All these factors contribute to creating very heterogeneous T cell products when whole PBMCs are used as a starting material. One could argue that the high response rate in both adult and pediatric patients with acute lymphoblastic leukemia infused with CD19-specific CAR-T cells supports the use of PBMCs as a starting source of T cells, regardless of their heterogeneity, as they contain all the T cell subsets needed for an effective immune response (2, 8, 9) . However, a more precise composition of the T cell products and in particular the enrichment in T cells with the highest potential for engraftment may become particularly relevant in other clinical settings, specifically in most solid tumors, in which the response rate to adoptive T cell therapies is currently significantly inferior compared with that for lymphoblastic leukemia.
Maintaining undifferentiated T cell populations
How can we preserve more immature and bona fide highly functional T cell subsets within infusion products without applying complex standard operating procedures? Activation, genetic manipulation, and ex vivo expansion of T cells inevitably induce their differentiation. This differentiation 
Conclusions and future directions
It remains unknown whether there is crosstalk among the mixed populations of T EM , T CM , and T SCM cells present in the infused products. Moreover, since CD4 + T cells are also present in unfractionated PBMCs and play a role in promoting the survival of engineered T cells (14) , determining whether this quorum-sensing phenomenon exists within the CD4 subset would greatly benefit the manufacturing of T cell modulation in T N cells, downregulating the expression of lymphoid-homing chemokine receptors (CD62L and CCR7) and memory-associated transcription factors. Overall, this leads to a reduction in antitumor efficacy of T N cell progeny expanded in the presence of T MEM cells.
This observation suggests that, to preserve the intrinsic properties of T N cell progenies, engineered T cells should be generated exclusively from T N cells selected from PBMCs (Figure 1 ). This mirrors the approach proposed by other investigators who optimized the selection of T CM cells for engineering purposes (13) . However, the mechanistic model proposed by Klebanoff et al. still keeps open the possibility of manipulating the culture conditions of unselected PBMCs to disrupt the signaling process can be stalled through manipulations during the expansion phase using cytokines, such as IL-7 and IL-15 instead of IL-2, to preserve more T SCM cells (7, 10) . In addition, activation of the Wnt-signaling pathway has been implied to delay T cell differentiation (11, 12) . However, in the current issue of the JCI, Klebanoff products. In addition to the application in cancer immunotherapy, this uncovered crosstalk between T MEM and T N cells may represent a physiologic immunoregulatory mechanism to favor T E cell differentiation over immune memory formation. Priming of T N cells in the presence of preexisting antigen-experienced T cells may be a signal for chronic persistent infection. Clearance of antigen by T E cells in this situation may be the priority over establishment of long-lived memory T cells. Moreover, since the ratio of T MEM to T N cells gradually increases with age, due to reduced output of T N cells from thymus, the discovered crosstalk between these subsets could be exploited to improve vaccination approaches in aged individuals.
